PI3K-delta

April 6, 2020April 6, 2020

ME-401 Put on FDA’s Fast Track for Previously Treated Follicular Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted fast track designation to MEI Pharma‘s investigational compound ME-401 for treating follicular lymphoma patients who received at least two prior therapies. A ... Read more

July 11, 2019

TG Therapeutics to Seek Accelerated Approval of Umbralisib for Marginal Zone Lymphoma

News

After positive feedback from the U.S. Food and Drug Administration, TG Therapeutics is planning to pursue accelerated approval for umbralisib (TGR-1202) as a treatment for patients with marginal zone lymphoma (MZL). ... Read more

October 18, 2018

MEI Pharma, BeiGene Will Evaluate New Combo Therapy for B-cell Cancers

News

A recent collaboration between MEI Pharma and BeiGene will test a combination of two investigational cancer therapies, ME-401 and zanubrutinib, for treating patients with B-cell cancers. Under the new partnership, MEI Pharma will amend its ongoing ... Read more

February 26, 2018February 26, 2018

Umbralisib Shows Promise in Treating Lymphoma, Leukemia in Phase 1 Clinical Trial

News

Umbralisib, being developed by TG Therapeutics, showed positive results in the treatment of chronic lymphocytic leukemia and lymphoma patients in a Phase 1 clinical trial. The study, “Umbralisib, a novel ... Read more

June 20, 2017June 20, 2017

Duvelisib Safe, Effective in Refractory Non-Hodgkin’s Lymphoma Patients, DYNAMO Study Shows

News

Treatment with Verastem’s duvelisib has shown sustained efficacy and safety in a trial with indolent non-Hodgkin’s lymphoma (iNHL) patients who had not responded well to Rituxan (rituximab) and chemotherapy or ... Read more